contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-plc-managers-transactions-pekka-mattila

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Joensuun Kauppa ja Kone Oy’s visit was short. It’s no longer on the list.

Insiders and the largest owners have mainly added shares, except for Citibank which sold about 200k and Tukiainen Tom 30k.                   Aiforia              Aiforia - Osakkeenomistajat    Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa laboratorioissa tehokkaan syväoppivan tekoälyohjelmiston.

Unfortunately, I won’t make it. The idea was to go there in person, but work commitments got in the way.  Today might see some fund report selling on the last day of the quarter, or something else. I’m ready to catch it, though, if there’s a bigger dip.

Is anyone here going to the annual general meeting on Thursday? Shareholders of Aiforia Technologies Plc are invited to the Annual General Meeting, which will be held on Thursday, April 2, 2026, at 10:00 AM in Sanomatalo’s Eliel Studio at Töölönlahdenkatu 2, Helsinki. The reception of those who have registered for the meeting and the distribution of voting slips at the meeting venue will begin at 9:30 AM.

AI informed me that tenders are being sought in that area  UK: Massive NHS-led consolidation of pathology services, creating large regional networks requiring sophisticated digital and AI tools.  For organizations looking to bid on 2026 tenders, the focus should be on demonstrating regulatory compliance (IVDR), seamless integration with existing pathology hardware, and validated clinical improvements in diagnostic accuracy. Key 2026 AI Pathology Procurement & Tenders West of England Pathology Network - Digital Histopathology (UK):  Scope: A massive initiative for an end-to-end digital histopathology pathway, including an Image Management System (IMS), scanners, and integrated 3rd party AI providers.  Value/Timeline: Estimated value around £50 million. The tender aims for a contract starting 1 October 2026, running until 2030/2033, creating a long-term partnership. All Wales Digital Cellular Pathology Managed Service (UK):  Scope: Digital pathology procurement with significant AI components.  Timeline: Estimated contract dates from 1 April 2026 to 2031.

Aiforia is recruiting an executive leader for European sales. They really emphasize in bold that the person must be UK-based.  What does Aiforia have in the UK that warrants such a clear restriction? Hasn’t it been somewhat on the sidelines until now, at least in clinical cases?            Aiforia Technologies Plc – 26 Mar 26              Key Account Executive Europe (UK-based) - Aiforia Technologies Plc    Aiforia's mission is to transform pathology image analysis with AI, enabling better care for each patient. About Aiforia Aiforia equips pathologists and scientists in preclinical and clinical l...

In a slightly different position in that digital pathology pipeline, but a small company like Aiforia, only with a valuation in the hundreds of millions. They validate the entire pipeline, and Aiforia has an excellent market position and technological leadership, with its moats. Grossly undervalued, due to the HEX sandbox and Finnish investors with empty pockets. It will correct itself someday.

Aiforia Technologies

Aiforia Technologies Plc, Company Release, Managers’ Transactions, April 1, 2026 at 9:20 a.m. EESTAiforia Technologies Plc – Managers’ Transactions – Pekka Mattila Aiforia Technologies Plc has...

Aiforia Technologies Plc, Company Release, Managers’ Transactions, April 1, 2026 at 9:20 a.m. EESTAiforia Technologies Plc – Managers’ Transactions – Pekka Mattila Aiforia Technologies Plc has received a notification from Pekka Mattila, Aiforia Technologies Plc's Board Chairman, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.____________________________________________Aiforia Technologies Plc - Managers' transactions - Mattila____________________________________________Person subject to the notification requirementName: Pekka MattilaPosition: Member of the Board/Deputy memberIssuer: Aiforia Technologies OyjLEI: 743700TJRVBX7420Y723Notification type: INITIAL NOTIFICATIONReference number: 147182/4/5____________________________________________Transaction date: 2026-03-13Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000507934Nature of transaction: EXERCISE OF A STOCK OPTION(X) Linked to stock option programmeTransaction details(1): Volume: 60000 Unit price: 0.02 EURAggregated transactions (1):Volume: 60000 Volume weighted average price: 0.02 EURFurther inquiries&nbsp;Antti Ojala, CFO, Aiforia Technologies Plc, tel. +358&nbsp;40 7202448 <a href="https://investors.aiforia.com/">https://investors.aiforia.com/</a>Certified Adviser&nbsp; UB Corporate Finance Ltd <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Aiforia Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.Find out more at <a href="http://aiforia.com/">www.aiforia.com</a>